Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Firm plans to take roughly $1.78 bil. in asset impairment charges in the fourth quarter of 2003 relating to "the decision to realign the portfolio, the planned stock-exchange listing of 'NewCo' and changes in the operating conditions for the future Bayer Material Science subgroup," Bayer announces Dec. 15. In September, Bayer announced corporate reorganization plans to give Bayer HealthCare legal independence as a carve-out of Bayer AG and to create Bayer Chemicals and Bayer Technology Services as separate entities (1"The Tan Sheet" Nov. 17, 2003, p. 6). The company's healthcare subgroup expects to report charges of about $405.3 mil. partially due to the consolidation of pharmaceutical research facilities, Bayer also noted...

You may also be interested in...

Bayer Shuffle To Result In Increased Consumer Care Focus

Bayer expects the establishment of its healthcare operations as a separate business unit will allow an increased focus on its consumer care business, CEO Werner Wenning said in a Nov. 11 earnings call

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts